Citigroup’s Barinthus Biotherapeutics BRNS Stock Holding History

Citigroup’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	6252
2022 Q1	$0	Buy	+2	New	+$16	﹤0.01%	6316

Other funds holding BRNS

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

LIP

Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's BRNS Position: Q2 2022 in Review

Citigroup sold out of Barinthus Biotherapeutics (BRNS) in Q2 2022, closing a stake of 2 shares.

Citigroup first reported a position in BRNS in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 13 funds tracked by Wall St. Rank hold BRNS as of Q2 2022.

Citigroup reported no remaining Barinthus Biotherapeutics position as of Q2 2022 after selling out during the quarter.
Citigroup sold 2 Barinthus Biotherapeutics shares in Q2 2022.
Citigroup first reported a position in Barinthus Biotherapeutics in Q1 2022 and held it in 1 quarter.
Citigroup's Barinthus Biotherapeutics position peaked at $0 in Q1 2022.
13 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.